



(12) Translation of
European patent specification

(11) NO/EP 3866799 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/407 (2006.01)

A61K 31/445 (2006.01)

A61K 31/4468 (2006.01)

A61K 31/4523 (2006.01)

A61K 31/502 (2006.01)

A61K 31/506 (2006.01)

A61K 31/517 (2006.01)

A61K 45/06 (2006.01)

A61P 9/14 (2006.01)

A61P 19/04 (2006.01)

C12N 9/12 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.03.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.12.06
(86)	European Application Nr.	19872573.1
(86)	European Filing Date	2019.10.16
(87)	The European Application's Publication Date	2021.08.25
(30)	Priority	2018.10.16, US, 201862746524 P 2018.10.18, US, 201862747587 P 2019.04.24, US, 201962838049 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	The Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA
(72)	Inventor	DIETZ, Harry C., 1104 Ryegate Road, Towson, MD 21286, USA BOWEN, Caitlin J., 2054 Bank Street, Baltimore, MD 21231, USA CALDERON GIADROSIC, Juan Francisco, Ricardo Lyon 3055-A, Ñuñoa, Santiago, 7770174, Chile
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge

(54) Title **COMPOSITIONS FOR TREATING VASCULAR EHLERS DANLOS SYNDROME**

(56) References

Cited:

DE-A1-102004 019 413

WO-A1-2018/160987

WO-A1-2017/079399

SHARP, TE et al.: "Protein Kinase C Inhibition With Ruboxistaurin Increases Contractility and Reduces Heart Size in a Swine Model of Heart Failure With Reduced Ejection Fraction", JACC: Basic to Translational Science, vol. 2, no. 6, 2017, pages 669-683, XP55710149,

LEPPANEN, T et al.: "Protein Kinase C and its Inhibitors in the Regulation of Inflammation: Inducible Nitric Oxide Synthase as an Example", Basic & Clinical Pharmacology & Toxicology, vol. 114, 2014, pages 37-43, XP055529503, DOI: 10.1111/bcpt.12139

HE, X et al.: "Targeting PKC in Human T Cells Using Sotrastaurin (AEB071) Preserves Regulatory T Cells and Prevents IL -17 Production", Journal of Investigative Dermatology, vol. 134, no. 4, 2014, pages 975-983, XP055806835,

BADE, MA et al.: "Endovascular abdominal aortic aneurysm repair in a patient with Ehlers-Danlos syndrome", Journal of Vascular Surgery, vol. 46, no. 2, 2007, pages 360-362, XP022694574, DOI: 10.1016/j.jvs.2007.03.045

LIN, Y et al.: "Genetic variants in PLCB4/PLCB1 as susceptibility loci for coronary artery aneurysm formation in Kawasaki disease in Han Chinese in Taiwan", Scientific Reports, vol. 5, 5 October 2015 (2015-10-05), pages 1-12, XP55710153,

DOYLE JEFFERSON J ET AL: "A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome", ELIFE, vol. 4, 27 October 2015 (2015-10-27), pages 1-18, XP55927548, DOI: 10.7554/eLife.08648 Retrieved from the Internet:

URL: https://elifesciences.org/download/aHR0cHM6Ly9jZG4uZWxpZmVzY2llbmNlcy5vcmcvYXJ0aWNsZXMvMDg2NDgvZWxpZmUtMDg2NDgtdjlucGRmP2Nhbm9uaWNhbFVyaT1odHRwczovL2VsaWZlc2NpZW5jZXMub3JnL2FydGljbGVzLzA4NjQ4/elife-08648-v2.pdf?_hash=r04QPSISb9gDPDGbczCnQo3Pylspiq7Uedu4zQ0JqK0=>

0cHM6Ly9jZG4uZWxpZmVzY2llbmNlcy5vcmcvYXJ0a

WNsZXMvMDg2NDgvZWxpZmUtMDg2NDgtdjlucGRmP2N

hbm9uaWNhbFVyaT1odHRwczovL2VsaWZlc2NpZW5jZ

XMub3JnL2FydGljbGVzLzA4NjQ4/elife-08648-v2

.pdf?_hash=r04QPSISb9gDPDGbczCnQo3Pylspiq7 Uedu4zQ0JqK0=>

BERIDZE NATALIA ET AL: "Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications", CARDIOLOGY IN REVIEW, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 20, no. 1, 31 December 2011 (2011-12-31), pages 4-7, XP009508098, ISSN: 1538-4683, DOI: 10.1097/CRD.0B013E3182342316

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk sammensetning for anvendelse i en fremgangsmåte for behandling av vaskulært Ehlers-Danlos syndrom (vEDS), sammensetningen omfattende en effektiv mengde av et middel, hvori midlet reduserer aktiviteten eller uttrykket av ekstracellulær signalregulert kinase (ERK) eller proteinkinase C (PKC) og hvori midlet velges fra ruboksistaurin, enzastaurin, sostrastaurin eller et farmasøytisk akseptabelt salt derav.
2. Den farmasøytiske sammensetningen for anvendelse ifølge krav 1, hvori midlet omfatter en effektiv mengde av enzastaurin.